8-K filed Jul 13, 2026 at 08:30 ET
Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy for retinitis pigmentosa in the MENA region. The deal includes upfront/near-term milestones up to $4 million, cumulative sales milestones up to $255 million, and a 22% royalty on net sales, with Ocugen manufacturing commercial supply. A definitive agreement is expected within 90 days, and the Phase 3 liMeliGhT trial topline readout is expected in Q1 2027.